Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs EPAM Systems Inc (EPAM) Price & Performance

CVS Health CorpTrade
EPAM Systems IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs EPAM Systems Inc — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while EPAM Systems Inc trades at $113.86 (market cap $5.59B). The key difference: CVS Health Corp is far larger — about 20.1× EPAM Systems Inc's market cap, and CVS Health Corp pays a 3.02% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and EPAM Systems Inc for 37 Days on average.

CVSEPAM
Market Cap
$112.49B$5.59B
Volume
8,467,392551,846
Sector
HealthTechnology
52-Week High
$110.60$221.40
52-Week Low
$70.08$76.04
Typical Hold Time
83 Days37 Days
Enterprise Value
$174.83B$4.95B
Dividend Yield
3.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.

CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.

EPAM Systems Inc

EPAM Systems trades at $108.32, down 0.91% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $3.38, beating estimates, and maintains strong profitability with a net margin of 7.15%. Recent news highlights partnerships in cloud security and AI-native revenue growth exceeding 11%.

The stock appears undervalued with a P/E of 14.7 and consensus price target of $119.00, offering potential upside. However, risks include slower North American growth and AI disruption to legacy services. Analyst sentiment is mixed with 59% buy ratings but recent institutional selling adds caution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

EPAM
46% Buy54% Sell
Avg holding period · 37 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM →